Oncology
Metastatic Solid Tumors
5
Pipeline Programs↗
36
Active Trials↗
27
Companies Involved↗
Metastatic Solid Tumors is an early-stage landscape with 5 programs across 27 companies. The most active players are BeiGene, Imclone, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 15
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
4programs
Small molecule250%
Monoclonal antibody250%
Modality classified for 80% of 5 pipeline programs.
Analysis
Trial Status
105
clinical trials
Completed49 · 47%
Recruiting21 · 20%
Terminated9 · 9%
Active, not recruiting8 · 8%
Unknown status7 · 7%
Not yet recruiting6 · 6%
Other5 · 5%
Clinical Trials
Trial Activity
105 trials
This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors
Recruiting·IInnovent Biologics Technology Limited (Shanghai R&D Center)·Phase 1·NCT07327632·300 enrolled
An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and/or Metastatic Solid Tumors
Recruiting·—·Phase 1·NCT06013111·9 enrolled
Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors
Recruiting·—·Phase 1·NCT07229768·4 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)